Colon Cancer

  • N. E. Rothschild
  • P. V. Woolley
Part of the UICC International Union Against Cancer book series (UICCI)


Although colorectal cancer is a common malignancy, we have made little progress in its treatment. Several problems contribute to this situation. First, although 5-fluorouracil (5-FU) is the single most active drug for colon cancer, its effect on patient survival is marginal. Second, extensive experience has failed to show that any drug combinations are better than 5-FU alone. Third, randomized prospective trials of 5-FU alone and with other agents have not altered the natural history of surgically resected colon cancer, although the drugs are theoretically of maximum effectiveness against minimal disease. Finally, empiric testing of drug development has been a very ineffective way of identifying active new agents for colon cancer [1].


Colon Cancer Proc ASCO Buthionine Sulfoximine Sonographic Guidance Resected Colon Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Woolley PV, von Hoff DD, Kyle GW et al. (1986) Biology of colon cancer resistance to treatment. In: Mastromarino AJ (ed) Biology and treatment of colorectal cancer metastasis. Nijhoff, Boston, pp 295–309CrossRefGoogle Scholar
  2. 2.
    Plowman J, Narayanan VL, Dykes D et al. (1986) Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70: 631–635PubMedGoogle Scholar
  3. 3.
    Drewinko B, Yang L (1985) Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Rep 69: 1391–1398PubMedGoogle Scholar
  4. 4.
    Lokich J, Ahlgren J, Gullo J et al. (1987) A randomized trial of standard bolus 5-FU vs. protracted infusional 5-FU in advanced colon cancer. Proc ASCO 6: 81Google Scholar
  5. 5.
    Hohn D, Stagg R, Friedman M et al. (1987) The NCOG randomized trial of intravenous vs. hepatic arterial FuDR for colon cancer metastatic to the liver. Proc ASCO 6: 85Google Scholar
  6. 6.
    Sugarbaker PH, Gianola FJ, Speyer JL et al. (1985) Prospective randomized trial of intravenous vs. intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Semin Oncol [Suppl 4] 12: 101–111Google Scholar
  7. 7.
    Buroker TR, Moertel, CG, Fleming TR et al. (1985) A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol 3: 1624–1631PubMedGoogle Scholar
  8. 8.
    Ortiz JE, Woolley PV (1987) A study of the synergistic effects of 5-fluorouracil and cisplatin on colon cancer cells using median effect analysis. Proc Am Assoc Cancer Res 6: 414Google Scholar
  9. 9.
    Glicksman AS, Lee ES, Leite D, Leith JT (1986) Production of increased cytotoxicity in human colon tumor cells after X-irradiation or drug treatment (cis-platinum, bleomycin, 5-fluorouracil) by pre-exposure to the differentiating agent N-methylformamide ( NMF ). Proc ASCO 5: 45Google Scholar
  10. 10.
    Dritschilo A, Grant EG, Harter KW et al. (1986) Interstitial radiation therapy for hepatic metastases: sonographic guidance for applicator placement. AJR 146: 275–278Google Scholar
  11. 11.
    Fojo AT, Ueda K, Slamon DJ et al. (1987) Expression of multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265–269PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • N. E. Rothschild
  • P. V. Woolley

There are no affiliations available

Personalised recommendations